FGC
PTGX icon

Financial Gravity Companies’s Protagonist Therapeutics PTGX Stock Holding History

Financial Gravity Companies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$0 Buy
+55
New +$436 ﹤0.01% 1486
2018
Q1 		$0 Buy
+2
New +$38 ﹤0.01% 1590

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Financial Gravity Companies's PTGX Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Protagonist Therapeutics (PTGX) in Q4 2018: 55 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1486 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in PTGX as recently as Q1 2018.

Financial Gravity Companies first reported a position in PTGX in Q1 2018 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold PTGX as of Q4 2018.

  • Financial Gravity Companies held 55 shares of Protagonist Therapeutics worth $0 as of Q4 2018.
  • Protagonist Therapeutics was a new Financial Gravity Companies position in Q4 2018.
  • Protagonist Therapeutics made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #1486 holding.
  • Financial Gravity Companies first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.